Liquid BX. Cell Free BRAF

What is Liquid Biopsy cell free BRFF mutation detection test?

Liquid Biopsy cell free BRFF mutation detection is a non-invasive blood test that detects BRAF gene mutations in circulating tumor DNA (ctDNA) found in the patient’s bloodstream. It focuses on identifying mutations like the BRAF V600E mutation without needing a tissue biopsy.

Why consider Liquid Biopsy cell free BRFF mutation detection test?

• To detect BRAF mutations when tissue biopsy is unavailable, risky, or insufficient.
• Helps in monitoring tumor genetics dynamically during treatment.
• Enables real-time assessment of tumor mutation status, useful for guiding therapy changes.
• Useful for detecting resistance mutations or tumor evolution.
• Less invasive, faster, and can be repeated over time.

Who should get tested for Liquid Biopsy cell free BRFF mutation detection test?

• Patients with cancers known to have BRAF mutations such as melanoma, colorectal cancer, Non-small cell lung cancer (NSCLC) and other solid tumors under targeted therapy.
• Patients where tissue biopsy is difficult or risky, monitoring response or resistance to targeted BRAF therapy is needed and for tracking minimal residual disease or recurrence.

More Information

OTHER NAMES: Cell-Free DNA BRAF Mutation Test, Plasma BRAF Mutation Analysis, Circulating Tumor DNA (ctDNA) BRAF Testing, Liquid Biopsy for BRAF, Blood-based BRAF Mutation Assay

The BRAF gene produces a protein that helps control cell growth through the MAPK signaling pathway.
A mutation at position V600 (usually called V600E) changes the BRAF protein, making it constantly active. This leads to uncontrolled cell division and contributes to cancer development. It is a driver mutation found in several cancers such as melanoma (skin cancer), colorectal cancer, thyroid cancer, non-small cell lung cancer (NSCLC) and others.